Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study
| Title: | Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study |
|---|---|
| Authors: | Morisco F.; Camera S.; Guarino M.; Tortora R.; Cossiga V.; Vitiello A.; Cordone G.; Caporaso N.; Di Costanzo G. G.; Zoli M.; Garuti F.; Neri A.; Piscaglia F.; Lenzi B.; Valente M.; Trevisani F.; Bolondi L.; Biselli M.; Caraceni P.; Cucchetti A.; Domenicali M.; Gramenzi A.; Magalotti D.; Serra C.; Venerandi L.; Cappelli A.; Golfieri R.; Mosconi C.; Renzulli M.; Giannini E. G.; Brunacci M.; Moscatelli A.; Pellegatta G.; Savarino V.; Caturelli E.; Roselli P.; Lauria V.; Pelecca G.; Dell'Isola S.; Ialungo A. M.; Rastrelli E.; Cabibbo G.; Camma C.; Attardo S.; Rossi M.; Cavani G.; Virdone R.; Affronti A.; Nardone G.; Felder M.; Mega A.; Ciccarese F.; Del Poggio P.; Olmi S.; Foschi F. G.; Bevilacqua V.; Dall'Aglio A. C.; Ercolani G.; Fiorini E.; Casadei Gardini A.; Lanzi A.; Mirici Cappa F.; Sacco R.; Mismas V.; Svegliati Barone G.; Schiada L.; Farinati F.; Gazzola A.; Murer F.; Pozzan C.; Vanin V.; Rapaccini G. L.; de Matthaeis N.; Gasbarrini A.; Rinninella E.; Olivani A.; Missale G.; Biasini E.; Di Marco M.; Balsamo C.; Vavassori E.; Masotto A.; Marchetti F.; Valerio M.; Marra F.; Aburas S.; Campani C.; Dragoni G.; Borzio F.; Benvegnu L.; Festi D.; Marasco G.; Ravaioli F. |
| Contributors: | Morisco, F.; Camera, S.; Guarino, M.; Tortora, R.; Cossiga, V.; Vitiello, A.; Cordone, G.; Caporaso, N.; Di Costanzo, G. G.; Zoli, M.; Garuti, F.; Neri, A.; Piscaglia, F.; Lenzi, B.; Valente, M.; Trevisani, F.; Bolondi, L.; Biselli, M.; Caraceni, P.; Cucchetti, A.; Domenicali, M.; Gramenzi, A.; Magalotti, D.; Serra, C.; Venerandi, L.; Cappelli, A.; Golfieri, R.; Mosconi, C.; Renzulli, M.; Giannini, E. G.; Brunacci, M.; Moscatelli, A.; Pellegatta, G.; Savarino, V.; Caturelli, E.; Roselli, P.; Lauria, V.; Pelecca, G.; Dell'Isola, S.; Ialungo, A. M.; Rastrelli, E.; Cabibbo, G.; Camma, C.; Attardo, S.; Rossi, M.; Cavani, G.; Virdone, R.; Affronti, A.; Nardone, G.; Felder, M.; Mega, A.; Ciccarese, F.; Del Poggio, P.; Olmi, S.; Foschi, F. G.; Bevilacqua, V.; Dall'Aglio, A. C.; Ercolani, G.; Fiorini, E.; Casadei Gardini, A.; Lanzi, A.; Mirici Cappa, F.; Sacco, R.; Mismas, V.; Svegliati Barone, G.; Schiada, L.; Farinati, F.; Gazzola, A.; Murer, F.; Pozzan, C.; Vanin, V.; Rapaccini, G. L.; de Matthaeis, N.; Gasbarrini, A.; Rinninella, E.; Olivani, A.; Missale, G.; Biasini, E.; Di Marco, M.; Balsamo, C.; Vavassori, E.; Masotto, A.; Marchetti, F.; Valerio, M.; Marra, F.; Aburas, S.; Campani, C.; Dragoni, G.; Borzio, F.; Benvegnu, L.; Festi, D.; Marasco, G.; Ravaioli, F. |
| Publisher Information: | Impact Journals LLC |
| Publication Year: | 2018 |
| Collection: | Padua Research Archive (IRIS - Università degli Studi di Padova) |
| Subject Terms: | Large HCC; Laser ablation; TACE |
| Description: | Background:Limited therapies are available for large (≥40 mm) unresectable hepatocellular carcinoma (HCC). Currently, the standard treatment with transarterial chemoembolisation (TACE) is unsatisfactory with high recurrence rate and limited effect on survival. Laser Ablation (LA) has emerged as a relatively new technique characterized by high efficacy and good safety. This study is aimed to evaluate the efficacy of LA in comparison to TACE in patients with large HCC. Methods: Eighty-two patients with a single HCC nodule ≥40 mm (BCLC stage A or B) were enrolled in this case-control study. Forty-one patients were treated with LA and 41 patients were treated with TACE. Response to therapy was evaluated according to the mRECIST criteria. Survival was calculated with Kaplan-Meier from the time of cancer diagnosis to death with values censored at the date of the last follow-up. Results: Twenty-six (63.4%) and 8 (19.5%) patients had a complete response after LA and TACE, respectively (p < 0.001). Subsequently we stratified the HCCs in 3 categories according to the nodule size: 40-50 mm, 51-60 mm, and > 60 mm. LA resulted superior to TACE especially in nodules ranging between 51 and 60 mm in diameter, with a complete response rate post-LA and post-TACE of 75% and 14.3%, respectively (p = 0.0133). The 36 months cumulative survival rate in patients treated with LA and TACE was 55.4% and 48.8%, respectively. The disease recurrence rates after LA and TACE were 19.5% and 75.0%, respectively. Conclusions: LA is a more effective therapeutic option than TACE in patients with solitary large HCC. |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/29707122; volume:9; issue:25; firstpage:17483; lastpage:17490; numberofpages:8; journal:ONCOTARGET; https://hdl.handle.net/11577/3421446 |
| DOI: | 10.18632/oncotarget.24756 |
| Availability: | https://hdl.handle.net/11577/3421446; https://doi.org/10.18632/oncotarget.24756 |
| Rights: | info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: | edsbas.D0F80741 |
| Database: | BASE |